Latest News
Ionis Releases Data Update from Phase 2 Study in Infants with SMA
Ionis Pharmaceuticals provided an update on its ongoing open-label Phase 2 clinical study of nusinersen in infants with spinal muscular atrophy (SMA) at the American Academy of Neurology (AAN) meeting. […]
Cure SMA and the SMA Community Featured by Astellas Pharmaceuticals
Cure SMA is featured by Astellas Pharmaceuticals as part of their new Changing Tomorrow Together website. Cure SMA Research Director Jill Jarecki contributed a spotlight piece about Cure SMA’s research […]
Annual SMA Conference to Host Panels on NDA Process and SMA Drugs in Development
One of the most significant aspects of the Annual SMA Conference is the bringing together of families and researchers in the same event. The 2016 Annual SMA Conference is poised […]
Cure SMA-Funded Researchers Receive NIH Grant
Cure SMA-funded researcher Peter Schultz has been awarded a four-year NIH grant of just over $2 million to support his research into small molecules to treat SMA. Cure SMA has […]
Adult Scholarships Offered for 2016 Annual SMA Conference
Cure SMA is pleased to announced that, thanks to a generous grant from The Dhont Family Foundation, we are offering conference scholarships to all adults with SMA. The scholarship covers […]
Global Genes Features Cure SMA in Patient Voice Project
Global Genes recently published, “From Molecules to Medicines: How Patients Can Share Their Voices Through the Drug Development Process.” This toolkit was the product of a collaboration between Global Genes […]